T he U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old.Previously ...

A single booster shot of MenQuadfi can be given to people ages 13 years or older who are at a continued risk of IMD if it’s been at least three years since their last meningococcal vaccine.

The FDA has approved expanded use of Sanofi Pasteur’s MenQuadfi, a meningococcal conjugate vaccine for children aged 2 to 10. MenQuadfi is now the first quadrivalent conjugate vaccine ...

Meningitis remains a significant health problem, affecting 2.5 million people annually and causing death and disability despite the availability of vaccines such as Sanofi’s MenQuadfi that ...

The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old. Previously approved ...